- Congestive Heart disease
- Angina pectoris
- Myocardial Ischemia
- Peripheral Artery Diseases
Cardiovascular Drugs Market size was valued at USD 146.51 billion in 2022, at a significant CAGR of 4.8% from 2023-2029. Cardiovascular drugs are the medications used in the treatment of various cardiovascular diseases. Cardiovascular diseases (CVD) include coronary artery diseases (CAD), myocardial infarction, angina pectoris, hypertension, cardiomyopathy, congenital heart disease, cardiac arrhythmia, peripheral artery diseases, atherosclerosis, and venous thrombosis among others. Majority of the cardiovascular diseases are preventable with cardiovascular drugs, however, in frequent conditions death may occur due to cardiovascular diseases. Global Market has tremendous growth rate over the forecast years owing to increase in the prevalence of various cardiovascular diseases and rise in R&D activities for the innovation of newer drugs. According to World Health Organization 2015, approximately 17.7 Mn deaths occured due to cardiovascular diseases around the world. Moreover, government support to control the diseases, rise in funding from public and private sectors for the R&D activities, and patent expiration of blockbuster are bolster the cardiovascular drugs market. Furthermore, acquisitions and mergers, product approvals, and promising pipeline drugs might upsurge the revenue of cardiovascular drugs market.
Cardiovascular Drugs Market Key Developments:
Fastest Growing Market
Increase in the prevalence of cardiovascular diseases, for instance, according to World health organization 2015, approximately 17.7 Mn people died from cardiovascular diseases around the globe, rise in R&D activities for the innovation of newer cardiovascular drugs, government support to increase the awareness about the cardiovascular diseases and treatment are anticipated to fuel the cardiovascular drugs market. Moreover, change in lifestyle, promising product pipeline, rise in prevalence of obesity, and wider access to cardiovascular drugs in the market are anticipated to propel the market. However, stringent regulatory guidelines for the product approval, high cost of treatment, and adverse effects associated with the medications are hampering the growth of cardiovascular drugs market.
The key segments covered in the Cardiovascular Drugs Market are technology, components, application, and end-users.
The Cardiovascular Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Cardiovascular Drugs Market key players are Capsa Solutions LLC (U.S.), Ergotron, Inc. (Melrose Industries plc) (UK), Enovate Medical (U.S.), Villard (France), Parity Medical (UK), InterMetro Industries Corp. (Emerson Electric) (U.S.), Humanscale Healthcare (U.S.), ITD GmBH (Germany), Compucaddy (U.S.), Advantech Co., Ltd. (China), Bytech Healthcare Ltd. (U.K.)
6. Global Cardiovascular Drugs Market Forecast, By Drug Class, 2018-2022 and Forecast, 2023-2029
7. Global Cardiovascular Drugs Market Forecast, By Route of Administration, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
8. Global Cardiovascular Drugs Market Forecast, By Distribution Channel, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
9. Global Cardiovascular Drugs Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
10. North America Cardiovascular Drugs MarketAnalysis,2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
16. Research Methodology